You didn't make it, but you hear far too often that drugs for management of chronic conditions are more profitable than cures for acute conditions, and that's what determines what goes into the development pipeline.

The truth is more complex than that. The reason that you don't see investment in antibiotics is that the low-hanging fruit is picked and you cannot use the new compounds unless as a treatment of last resort, and sales would be far too low to be profitable. They will be needed, though, in the medium term. The financing model in pharma is broken and there is no change on the horizon in that department.